Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 19/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29733437 | 1.00 | CNR2 (0.48) | CNR2ABCB11PDE4APDE4BPDE4C | |
| SCHEMBL17207630 | 0.90 | CNR2 (0.49) | CNR2ABCB11PDE4APDE4BPDE4C | |
| SCHEMBL15764316 | 0.88 | CNR2 (0.47) | CNR2ABCB11PDE4APDE4BPDE4C | |
| SCHEMBL72985 | 0.88 | PDE4D (0.59) | CNR2ABCB11PDE4APDE4BPDE4C | |
| SCHEMBL17207628 | 0.83 | PDE4A (0.43) | CNR2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL17201804 | 0.83 | PDE4D (0.55) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL17207625 | 0.82 | PDE4A (0.42) | CNR2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL15397615 | 0.82 | PDE4A (0.43) | CNR2ABCB11PDE4APDE4BPDE4C | |
| SCHEMBL1978878 | 0.82 | CNR2 (0.50) | CNR2CNR1 | |
| SCHEMBL1978884 | 0.81 | ABCB11 (0.46) | CNR2ABCB11PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2935239-B1 | PROCESS FOR PREPARING 4-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLORO-1-OXIDO-4-PYRIDYL)-5-METHOXYPYRIDINE-2-CARBOXAMIDE | SANOFI SA (FR) | 2018-08-29 | — | — | EP | claimed |
| US-9611250-B2 | Process for preparing 4-(cyclopropylmethoxy)-N-(3,5-dichloro-1-oxido-4-pyridyl)-5-methoxypyridine-2-carboxamide | SANOFI (FR) | 2017-04-04 | — | — | US | claimed |
| US-9533953-B2 | Method of preparation of crystal forms of 4-(cyclopropylmethoxy)-n-(3,5-dichloro-1-oxidopyridyn-4-yl)-5-methoxypyridine-2-carboxamide and crystal forms thereof | SANOFI (FR) | 2017-01-03 | — | — | US | claimed |
| US-9393236-B2 | Use of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxido-4-pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide in the treatment of cranial traumas | SANOFI (FR) | 2016-07-19 | — | — | US | claimed |
| US-20150322014-A1 | METHOD OF PREPARATION OF CRYSTAL FORMS OF 4-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLORO-1-OXIDOPYRIDYN-4-YL)-5-METHOXYPYRIDINE-2-CARBOXAMIDE AND CRISTAL FORMS THEREOF | SANOFI (FR) | 2015-11-12 | — | — | US | claimed |
| US-20150307474-A1 | PROCESS FOR PREPARING 4-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLORO-1-OXIDO-4-PYRIDYL)-5-METHOXYPYRIDINE-2-CARBOXAMIDE | SANOFI (FR) | 2015-10-29 | — | — | US | claimed |
| EP-2935239-A1 | PROCESS FOR PREPARING 4-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLORO-1-OXIDO-4-PYRIDYL)-5-METHOXYPYRIDINE-2-CARBOXAMIDE | SANOFI (FR) | 2015-10-28 | — | — | EP | claimed |
| WO-2014083106-A1 | PROCESS FOR PREPARING 4-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLORO-1-OXIDO-4-PYRIDYL)-5-METHOXYPYRIDINE-2-CARBOXAMIDE | SANOFI (FR) | 2014-06-05 | — | — | WO | claimed |
| US-8592443-B2 | Use of 4 cyclopropylmethoxy-N-(3,5 dichloro-1 oxido-pyridin-4 yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of spinal cord traumas | SANOFI (FR) | 2013-11-26 | — | — | US | claimed |
| EP-2146713-B1 | USE OF 4-CYCLOPROPYLMETHOXY-N-(3,5-DICHLORO-1-OXIDOPYRIDIN-4-YL)-5-(METHOXY)PYRIDINE-2-CARBOXAMIDE FOR THE TREATMENT OF CRANIAL TRAUMAS | SANOFI SA (FR) | 2011-11-09 | — | — | EP | claimed |
| EP-2146714-B1 | USE OF 4-CYCLOPROPYLMETHOXY-<I>N</I>-(3,5-DICHLORO-1-OXIDOPYRIDIN-4-YL)-5-(METHOXY)PYRIDINE-2-CARBOXAMIDE FOR THE TREATMENT OF MOTOR DISORDERS RELATED TO PARKINSON'S DISEASE | SANOFI AVENTIS (FR) | 2011-06-22 | — | — | EP | claimed |
| EP-2150253-B1 | USE OF 4-CYCLOPROPYLMETHOXY-N-(3,5-DICHLORO-1-OXIDOPYRIDIN-4-YL)-5-(METHOXY)PYRIDINE-2-CARBOXAMIDE FOR THE TREATMENT OF SPINAL CORD TRAUMAS | SANOFI AVENTIS (FR) | 2011-03-30 | — | — | EP | claimed |
| US-20100137370-A1 | USE OF 4 CYCLOPROPYLMETHOXY-N-(3,5 DICHLORO-1 OXIDO-PYRIDIN-4 YL)-5-(METHOXY)PYRIDINE-2 CARBOXAMIDE FOR THE TREATMENT OF SPINAL CORD TRAUMAS | SANOFI-AVENTIS (FR) | 2010-06-03 | — | — | US | claimed |
| US-20100130553-A1 | USE OF 4-CYCLOPROPYLMETHOXY-N-(3,5-DICHLORO-1-OXIDO-4-PYRIDIN-4-YL)-5-(METHOXY)PYRIDINE-2-CARBOXAMIDE IN THE TREATMENT OF CRANIAL TRAUMAS | SANOFI-AVENTIS (FR) | 2010-05-27 | — | — | US | claimed |
| US-20100130554-A1 | USE OF 4-CYCLOPROPYLMETHOXY-N-(3,5-DICHLORO-1-OXIDOPYRIDIN-4-YL)-5-(METHOXY)PYRIDINE-2-CARBOXAMIDE FOR THE TREATMENT OF MOTOR DISORDERS RELATED TO PARKINSON'S DISEASE | SANOFI-AVENTIS (FR) | 2010-05-27 | — | — | US | claimed |
| US-20250120957-A1 | TREATMENT OF NEUROPSYCHIATRIC DISORDERS WITH TILIVAPRAM | ALTO NEUROSCIENCE, INC. | 2025-04-17 | — | — | US | disclosed |
| US-20230117508-A1 | ENHANCEMENT OF CAMP SIGNALING AS A COMBINATION DRUG STRATEGY FOR THE TREATMENT OF PSYCHIATRIC AND NEUROLOGICAL DISORDERS IN WHICH DEPRESSIVE, ANHEDONIA, MOTIVATION-RELATED OR COGNITION-RELATED DYSFUNCTION EXISTS | ALTO NEUROSCIENCE, INC. | 2023-04-20 | — | — | US | disclosed |
| WO-2008145841-A1 | USE OF 4-CYCLOPROPYLMETHOXY-N-(3,5-DICHLORO-1-OXIDOPYRIDIN-4-YL)-5-(METHOXY)PYRIDINE-2-CARBOXAMIDE FOR THE TREATMENT OF MOTOR DISORDERS RELATED TO PARKINSON'S DISEASE | SANOFI-AVENTIS (FR) | 2008-12-04 | — | — | WO | disclosed |
| WO-2008145841-A1 | USE OF 4-CYCLOPROPYLMETHOXY-N-(3,5-DICHLORO-1-OXIDOPYRIDIN-4-YL)-5-(METHOXY)PYRIDINE-2-CARBOXAMIDE FOR THE TREATMENT OF MOTOR DISORDERS RELATED TO PARKINSON'S DISEASE | SANOFI-AVENTIS (FR) | 2008-12-04 | — | — | WO | disclosed |
| WO-2008145841-A1 | USE OF 4-CYCLOPROPYLMETHOXY-N-(3,5-DICHLORO-1-OXIDOPYRIDIN-4-YL)-5-(METHOXY)PYRIDINE-2-CARBOXAMIDE FOR THE TREATMENT OF MOTOR DISORDERS RELATED TO PARKINSON'S DISEASE | SANOFI-AVENTIS (FR) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250120957-A1 | TREATMENT OF NEUROPSYCHIATRIC DISORDERS WITH TILIVAPRAM | SLC6A3, SLC6A4, COMT | CNR2 2074/4885ABCB11 3297/4885PDE4A 135/4885 |
| US-20150322014-A1 | METHOD OF PREPARATION OF CRYSTAL FORMS OF 4-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLORO-1-OXIDOPYRIDYN-4-YL)-5-METHOXYPYRIDINE-2-CARBOXAMIDE AND CRISTAL FORMS THEREOF | COX5B, COX5A, CYCS | CNR2 529/4885ABCB11 2362/4885PDE4A 1031/4885 |
| US-20150307474-A1 | PROCESS FOR PREPARING 4-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLORO-1-OXIDO-4-PYRIDYL)-5-METHOXYPYRIDINE-2-CARBOXAMIDE | CYP3A4, CYP4B1, CYP3A5 | CNR2 47/4885ABCB11 1052/4885PDE4A 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.